The 2mWT was administered at session 4 and 7 revealed improvement in the patient’s endurance by ambulating 96 feet in 2 minutes at discharge compared to 78 feet at re-evaluation (Table 3). The improvement in the patent’s distance (18 feet) did not met the published minimal detectable change (MDC) value for individuals with MS (MDC=19.21 meters/63.02 feet) (Gijbels). An improvement in the patient’s fall risk status was indicated using the BBS. The patient improved from high risk at initial evaluation to medium fall risk at discharge exceeding the reported MDC for an initial score of 0-24 points for the elderly (MDC=4.6 points) (Donoghue). The patient scored higher, improving in all items except for standing with one foot in front and standing on one leg where no change was made. There was no significant improvement on the patients MS walking scale score; her high score indicates that she has a strong perception that MS greatly impacts her ability to walk. No MDC values have been reported for the MSWS-12. Lastly, the patient’s score on the LEFS improved but remained under the published MDC value for various lower extremity injuries (MDC= 9 points) (Binkley). The patient reported on the LEFS at discharge less difficulty standing, preforming light activities around the house and walking between rooms. All STG and LTG were meet at the time of discharge. The patient’s ability to complete transfers in and out of bed and chairs, stand for prolonged periods of time, static and dynamic standing posture and ambulate greater distances significantly improved with less fatigability and greater ease. Her patellofemoral pain was unable to be completely managed be but reductions in pain were achieved along with improved alignment of the left patella thus minimizing lateral deviation of the patella. The patient was provided with an updated HEP and the necessary
The 2mWT was administered at session 4 and 7 revealed improvement in the patient’s endurance by ambulating 96 feet in 2 minutes at discharge compared to 78 feet at re-evaluation (Table 3). The improvement in the patent’s distance (18 feet) did not met the published minimal detectable change (MDC) value for individuals with MS (MDC=19.21 meters/63.02 feet) (Gijbels). An improvement in the patient’s fall risk status was indicated using the BBS. The patient improved from high risk at initial evaluation to medium fall risk at discharge exceeding the reported MDC for an initial score of 0-24 points for the elderly (MDC=4.6 points) (Donoghue). The patient scored higher, improving in all items except for standing with one foot in front and standing on one leg where no change was made. There was no significant improvement on the patients MS walking scale score; her high score indicates that she has a strong perception that MS greatly impacts her ability to walk. No MDC values have been reported for the MSWS-12. Lastly, the patient’s score on the LEFS improved but remained under the published MDC value for various lower extremity injuries (MDC= 9 points) (Binkley). The patient reported on the LEFS at discharge less difficulty standing, preforming light activities around the house and walking between rooms. All STG and LTG were meet at the time of discharge. The patient’s ability to complete transfers in and out of bed and chairs, stand for prolonged periods of time, static and dynamic standing posture and ambulate greater distances significantly improved with less fatigability and greater ease. Her patellofemoral pain was unable to be completely managed be but reductions in pain were achieved along with improved alignment of the left patella thus minimizing lateral deviation of the patella. The patient was provided with an updated HEP and the necessary